Kura Oncology (KURA) Other Non-Current Liabilities (2014 - 2026)

Kura Oncology (KURA) has 13 years of Other Non-Current Liabilities data on file, last reported at $3.4 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $3.4 million, up 60.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (up 60.68% YoY), and the FY2025 annual result was $3.2 million, up 76.32% from the prior year.
• Other Non-Current Liabilities rose to $3.4 million in Q1 2026 per KURA's latest filing, from $3.2 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $3.4 million in Q1 2026 and troughed at $265000.0 in Q4 2022.
• A 5-year average of $1.4 million and a median of $951000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities decreased 29.33% in 2022, then jumped 170.94% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $265000.0 in 2022, then soared by 166.04% to $705000.0 in 2023, then soared by 154.61% to $1.8 million in 2024, then jumped by 76.32% to $3.2 million in 2025, then climbed by 8.59% to $3.4 million in 2026.
• Business Quant data shows KURA's Other Non-Current Liabilities at $3.4 million in Q1 2026, $3.2 million in Q4 2025, and $3.0 million in Q3 2025.